UK's Redx Pharma signs oncology collaboration with Pierre Fabre

7 March 2014

UK-based drug discovery company Redx Pharma and privately-owned French health care company Pierre Fabre have completed a collaboration and option agreement in cancer research.

The exclusive deal will see Redx and Pierre Fabre Research Institute (IRPF) work together on the evaluation and development of a small-molecule program for an undisclosed oncology target. Following the first stage of the collaboration, IRPF will have the option to enter into exclusive negotiations to license global rights for the program in selected cancer indications. The financial terms of the agreement have not been disclosed but the deal has been described as “a highly significant milestone in the company's development.”

Reinforcing pipeline

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK